Inhibiting b-cell receptor signaling pathways in chronic lymphocytic Leukemia

Current Hematologic Malignancy Reports

Volumn 7, Issue 1, 2012, Pages 26-33

  Burger, Jan A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

B lymphocytes; B cell receptor; BCR; Btk; CAL 101; Chemokine receptors; Chronic lymphocytic leukemia; CLL; CXCR4; CXCR5; Fostamatinib; Kinase inhibitors; Microenvironment; PCI 32765; PI3K delta; Signaling pathways; Syk; Therapy; ZAP 70

Indexed keywords

5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE INHIBITOR; FOSTAMATINIB; IBRUTINIB; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE SYK INHIBITOR; PROTEIN KINASE ZAP 70; ANTINEOPLASTIC AGENT; CAL 101; LYMPHOCYTE ANTIGEN RECEPTOR; OXAZINE DERIVATIVE; PCI 32765; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; R788 COMPOUND;

ARTICLE; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; LEUKEMIA REMISSION; LYMPHADENOPATHY; LYMPHOCYTE COUNT; RHEUMATOID ARTHRITIS; DRUG ANTAGONISM; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; OXAZINES; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PURINES; PYRAZOLES; PYRIDINES; PYRIMIDINES; QUINAZOLINONES; RECEPTORS, ANTIGEN, B-CELL; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84859256604     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0104-z     Document Type: Article

References (81)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-15.
2. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367-75.
3. Stein H, Bonk A, Tolksdorf G, Lennert K, Rodt H, Gerdes J. Immunohistologic analysis of the organization of normal lymphoid tissue and non-Hodgkin's lymphomas. J Histochem Cytochem. 1980;28(8):746-60.
4. Patten PE, Buggins AG, Richards J, Wotherspoon A, Salisbury J, Mufti GJ, et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood. 2008;111 (10):5173-81.
5. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. The Journal of Clinical Investigation. 2005;115(3):755-64. (Pubitemid 40322252)
6. Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007;110(9):3316-25. (Pubitemid 350106325)
7. Bhattacharya N, Diener S, Idler IS, Barth TF, Rauen J, Habermann A, et al. Non-malignant B cells and chronic lymphocytic leukemia cells induce a pro-survival phenotype in CD14+ cells from peripheral blood. Leukemia. 2011;25(4):722-6.
8. Ruan J, Hyjek E, Kermani P, Christos PJ, Hooper AT, ColemanM, et al. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clin Cancer Res. 2006;12(19):5622-31. (Pubitemid 44629588)
9. Ghia P, Strola G, Granziero L, Geuna M, Guida G, Sallusto F, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol. 2002;32(5):1403-13. (Pubitemid 34546268)
10. Ghia P, Caligaris-Cappio F. The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. AdvCancer Res. 2000;79:157-73. (Pubitemid 30228123)
11. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117(2):563-574. This study provides the first direct evidence for BCR activation in CLL in the lymphatic tissues.
12. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004;103(12):4389-95. (Pubitemid 38745961)
13. Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009; 13(13):3050-8. This paper characterizes CCL3 gene upregulation in CLL cells as response to the microenvironment, particularlyafter BCR activation.
14. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194(11):1639-47. (Pubitemid 33126814)
15. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100 (13):4609-14. (Pubitemid 35429705)
16. Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, Kolitz J, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004;200(4):519-25. (Pubitemid 39121908)
17. Widhopf 2nd GF, Rassenti LZ, Toy TL, Gribben JG, Wierda WG,Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004;104(8):2499-504. (Pubitemid 39331853)
18. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia:lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol. 2003;21:841-94. (Pubitemid 37174549)
19. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-celllymphoma. Nature. 2010;463(7277):88-92.
20. Pighi C, Gu TL, Dalai I, Barbi S, Parolini C, Bertolaso A, et al.Phospho-proteomic analysis of mantle cell lymphoma cellssuggests a pro-survival role of B-cell receptor signaling. Cell Oncol (Dordr). 2011;34(2):141-53.
21. Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132(3):303-16. (Pubitemid 43381537)
22. Cecconi D, Zamo A, Bianchi E, Parisi A, Barbi S, Milli A, et al.Signal transduction pathways of mantle cell lymphoma: a phosphoproteome-based study. Proteomics. 2008;8(21):4495-506.
23. Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E, et al. The molecular signature of mantle celllymphoma reveals multiple signals favoring cell survival. Cancer Res. 2003;63(23):8226-32. (Pubitemid 37549472)
24. Rizzatti EG, Falcao RP, Panepucci RA, Proto-Siqueira R, Anselmo-Lima WT, Okamoto OK, et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signallingpathways. Br J Haematol. 2005;130(4):516-26. (Pubitemid 43899754)
25. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676-9. (Pubitemid 351432507)
26. Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science. 2002;296(5573):1641-2. (Pubitemid 34579149)
27. Wang LD, Clark MR. B-cell antigen-receptor signalling in lymphocyte development. Immunology. 2003;110(4):411-20. (Pubitemid 37521870)
28. Reth M. Antigen receptors on B lymphocytes. Annu RevImmunol. 1992;10:97-121.
29. Liu W, Meckel T, Tolar P, Sohn HW, Pierce SK. Intrinsic properties of immunoglobulin IgG1 isotype-switched B cell receptors promote microclustering and the initiation of signaling. Immunity. 2010;32(6):778-89.
30. Bernal A, Pastore RD, Asgary Z, Keller SA, Cesarman E, LiouHC, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood. 2001;98(10):3050-7.
31. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediatingantiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 2008;111(2):846-55.
32. Turner M, Mee PJ, Costello PS, Williams O, Price AA, Duddy LP, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature. 1995;378(6554):298-302.
33. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 1995;378(6554):303-6.
34. Young RM, Hardy IR, Clarke RL, Lundy N, Pine P, Turner BC, et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood. 2009;113(11):2508-16.
35. Zarbock A, Lowell CA, Ley K. Spleen tyrosine kinase Syk is necessary for E-selectin-induced alpha(L)beta(2) integrinmediated rolling on intercellular adhesion molecule-1. Immunity. 2007;26(6):773-83. (Pubitemid 46907666)
36. Ganju RK, Brubaker SA, Chernock RD, Avraham S, Groopman JE. Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk. J Biol Chem. 2000;275(23):17263-8. (Pubitemid 30430758)
37. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week,randomized, placebo-controlled trial. Arthritis Rheum. 2008;58 (11):3309-18.
38. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M,et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006;319(3):998-1008.
39. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115(13):2578-85. This is the first report about the clinical activity of an inhibitor of a BCR-associated kinase, Syk.
40. Genevier HC, Hinshelwood S, Gaspar HB, Rigley KP, Brown D,Saeland S, et al. Expression of Bruton's tyrosine kinase protein within the B cell lineage. European journal of immunology. 1994;24(12):3100-5.
41. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72(2):279-90. (Pubitemid 23044942)
42. Conley ME, Dobbs AK, Farmer DM, Kilic S, Paris K, Grigoriadou S, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009;27:199-227.
43. Petro JB, Rahman SM, Ballard DW, Khan WN. Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med. 2000;191(10):1745-54.
44. Spaargaren M, Beuling EA, Rurup ML, Meijer HP, Klok MD, Middendorp S, et al. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med. 2003;198(10):1539-50. (Pubitemid 37467168)
45. Ortolano S, Hwang IY, Han SB, Kehrl JH. Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol. 2006;36(5):1285-95.
46. de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW, et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007;26(1):93-104. (Pubitemid 46109347)
47. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al: The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107 (29):13075-80. This article presents a characterization of the firstin-man Btk inhibitor.
48. Burger JA, O'Brien S, Fowler N, Advani R, Sharman JP, Furman RR, et al. The Bruton's tyrosine kinase inhibitor, PCI-32765, iswell tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): an update on ongoing phase 1 studies [abstract]. Blood. 2010;116(21):32a.
49. Advani R, Sharman JP, Smith SM, Pollyea DA, Boyd TE, Grant BW, et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: evidence of antitumor activity from a phase I study [abstract]. J Clin Oncol. 2010;2010:8012a.
50. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117 (23):6287-96.
51. Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009;139(3):573-86.
52. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3 (4):317-30. (Pubitemid 37328684)
53. Jou ST, Carpino N, Takahashi Y, Piekorz R, Chao JR, Carpino N, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. MolCell Biol. 2002;22(24):8580-91. (Pubitemid 35397173)
54. Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, etal. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med. 2002;196(6):753-63.
55. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, et al. Impaired B and Tcell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 2002;297(5583):1031-4. (Pubitemid 34856039)
56. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, PeschelC, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood. 2002;100(10):3741-8. (Pubitemid 35303946)
57. Kienle D, Benner A, Krober A, Winkler D, Mertens D, Buhler A, et al. Distinct gene expression patterns in chronic lymphocyticleukemia defined by usage of specific VH genes. Blood. 2006;107 (5):2090-3. (Pubitemid 43289393)
58. Edelmann J, Klein-Hitpass L, Carpinteiro A, Fuhrer A, Sellmann L, Stilgenbauer S, et al. Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk Res. 2008;32(10):1565-72.
59. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood.1999;94(11):3658-67.
60. Lannutti BJ, Meadows SA, Herman SE, Kashishian A,Steiner B, Johnson AJ, et al. CAL-101, a p110{delta} selectivephosphatidylinositol-3-kinase inhibitor for the treatment of Bcellmalignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591-4.
61. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078-88.
62. Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 116(9):1460-8.
63. Furman RR, Byrd JC, Brown JR, Coutre SE, Benson Jr DM, Wagner-Johnston ND, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. Blood. 2010;116 (21):31a.
64. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 3?-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603-12.These in vitro and correlative data explain the clinical activity ofthe PI3K delta inhibitor CAL-101.
65. Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, RassentiL, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood. 2005;105(5):2036-41. (Pubitemid 40731789)
66. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ,Wierda WG, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor,R406. Blood. 2009;114(5):1029-37.
67. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, et al. CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011;117 (5):1662-9. This paper describes CCL3 as a BCR-related new prognostic marker in CLL.
68. Chan AC, Iwashima M, Turck CW, Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell. 1992;71(4):649-62.
69. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101(12):4944-51. (Pubitemid 36857758)
70. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764-75. (Pubitemid 36514707)
71. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351(9):893-901. (Pubitemid 39096916)
72. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, Weiss A, et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2008;111(5):2685-92.
73. Richardson SJ, Matthews C, Catherwood MA, Alexander HD, Carey BS, Farrugia J, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2006;107 (9):3584-92.
74. Messmer D, Fecteau JF, O'Hayre M, Bharati IS, Handel TM, Kipps TJ. Chronic lymphocytic leukemia cells receive RAFdependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood. 2011;117(3):882-9.
75. Schall TJ, Bacon K, Camp RD, Kaspari JW, Goeddel DV. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med. 1993;177(6):1821-6.
76. Krzysiek R, Lefevre EA, Zou W, Foussat A, Bernard J, Portier A, et al. Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells. J Immunol. 1999;162(8):4455-63. (Pubitemid 29314842)
77. Eberlein J, Nguyen TT, Victorino F, Golden-Mason L, Rosen HR, Homann D. Comprehensive assessment of chemokine expressionprofiles by flow cytometry. J Clin Invest. 2010;120(3):907-23.
78. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 2000;13(2):199-212.
79. Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D, et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res. 2009;69(9):4001-9.
80. Palacios F, Moreno P, Morande P, Abreu C, Correa A, Porro V, et al. High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. Blood. 2010;115(22):4488-96.
81. Hamed H, Zaki S. Role of CCL3 protein (monocyte inflammatory protein-1 alpha) in lymphoid malignancy. Egypt J Immunol. 2007;14(1):63-72.